Personalis Debt to Equity Ratio 2018-2024 | PSNL

Current and historical debt to equity ratio values for Personalis (PSNL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Personalis debt/equity for the three months ending June 30, 2024 was 0.00.
Personalis Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-06-30 $0.07B $0.11B 0.65
2024-03-31 $0.08B $0.12B 0.62
2023-12-31 $0.10B $0.13B 0.74
2023-09-30 $0.08B $0.15B 0.50
2023-06-30 $0.07B $0.18B 0.41
2023-03-31 $0.08B $0.19B 0.41
2022-12-31 $0.08B $0.22B 0.34
2022-09-30 $0.08B $0.24B 0.31
2022-06-30 $0.09B $0.27B 0.35
2022-03-31 $0.09B $0.29B 0.33
2021-12-31 $0.09B $0.31B 0.28
2021-09-30 $0.08B $0.33B 0.25
2021-06-30 $0.05B $0.34B 0.13
2021-03-31 $0.05B $0.35B 0.14
2020-12-31 $0.05B $0.20B 0.26
2020-09-30 $0.05B $0.20B 0.22
2020-06-30 $0.05B $0.09B 0.56
2020-03-31 $0.05B $0.10B 0.53
2019-12-31 $0.05B $0.11B 0.47
2019-09-30 $0.05B $0.11B 0.43
2019-06-30 $0.08B $0.12B 0.64
2019-03-31 $0.00B $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B $0.00B 0.00
2018-06-30 $0.00B $0.00B 0.00
2017-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.270B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00